Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Formoterol 6mcg + Budesonide 400mcg Rota Capsule
Therapeutic Category
Pulmonary, Respiratory, Asthma
Dosage Form
Capsule
Packaging Type
Capsules
Packaging
30
Price
₹222/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Buditerm F 400 Capsule is a combination medication containing Formoterol (6mcg) and Budesonide (400mcg). It is specially designed for the management of respiratory conditions like Asthma and Chronic Obstructive Pulmonary Disease (COPD). The formulation combines two key ingredients: Formoterol, a long-acting bronchodilator, and Budesonide, a corticosteroid. This combination helps open up the airways and reduce inflammation, providing patients with better control over their respiratory conditions and helping to prevent flare-ups.
Formoterol, as a beta-agonist, works by relaxing the muscles around the airways, making it easier to breathe and relieving symptoms like wheezing, shortness of breath, and chest tightness. Budesonide, a corticosteroid, helps reduce inflammation in the airways, which is essential in controlling chronic respiratory conditions. This combination ensures both immediate and long-term relief, improving overall lung function and quality of life for patients suffering from asthma and COPD.
Common side effects include headache, throat irritation, and muscle cramps. Severe side effects like tachycardia or tremors may occur in rare cases.
Buditerm F 400 Dry Powder Inhaler Capsule is used for the management of Asthma and COPD to relieve symptoms and improve breathing.
Not for acute asthma attacks; consult a doctor for proper use and dosage.
Store at room temperature (15°C to 30°C) in a dry place, away from light and moisture.
Composition : Fluticasone Propionate 500mcg + Formoterol Fumarate 12mcg Life Cap
Composition : Formoterol (6mcg) + Budesonide (200mcg) Inhaler
Composition : Salmeterol (50mcg) + Fluticasone Propionate (500 mcg)
Composition : Fluticasone Propionate 250mcg + Formoterol Fumarate 6mcg Life Cap
Composition : Salmeterol (50mcg) + Fluticasone Propionate (250mcg)
Composition : Formoterol (20mcg) + Budesonide (0.5mg) Respule
Composition : Levosalbutamol (1.25mg) + Budesonide (0.5mg) Respule
Composition : Levosalbutamol (1.25mg) + Ipratropium (500mcg)
Composition : Salmeterol (25mcg) + Fluticasone Propionate (250mcg)
Composition : Salmeterol (25mcg) + Fluticasone Propionate (500mcg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Budesonide 400 mcg + Formoterol 6 mcg is a combination respiratory therapy indicated for the long-term management of moderate to severe asthma and Chronic Obstructive Pulmonary Disease (COPD). Budesonide is an inhaled corticosteroid (ICS) that reduces airway inflammation and prevents exacerbations. Formoterol is a long-acting beta-2 agonist (LABA) that provides prolonged bronchodilation and improves breathing. This higher-strength formulation is commonly prescribed for patients requiring enhanced anti-inflammatory control and long-term respiratory maintenance, making it a valuable product in the pulmonology and respiratory care segment.
Medical distributors and wholesalers can benefit from consistent demand from pulmonologists, chest physicians, and hospitals. Asthma and COPD require long-term maintenance therapy, resulting in regular refill prescriptions, strong patient retention, and recurring sales opportunities.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in respiratory, pulmonology, and inhalation therapy segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high chronic disease prevalence, specialist-driven prescriptions, and long-term treatment continuity, making it a stable, high-value, and repeat-order pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in respiratory and inhalation therapy products can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the pulmonology and respiratory care segment.